Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.
Omid Hamid, MD, chief of Translational Research and Immunotherapy at The Angeles Clinic, talks about patient responses with single-agent immunotherapy and combination therapies in melanoma.
Hamid explains that the response rate for single-agent immunotherapy treatment is approximately 40%, and for combination treatments, it is approximately 57%. However, these data do not give much information about the long-term benefits of these therapies. Hopefully, comparisons of the overall survival with combination treatments and with single-agent treatment will be forthcoming.